CoChat

DHEA, DHEAS and PCOS

Goodarzi, Mark O., Carmina, Enrico, Azziz, Ricardo · 2015 · The Journal of Steroid Biochemistry and Molecular Biology
Cited by 188

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jsbmb.2014.06.003

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 132

  1. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), Hum. Reprod., 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
  2. NIH Office of Disease Prevention: Evidence-based Methodology Workshop on Polycystic Ovary Syndrome (PCOS), Dec. 3–5, 2012-Final report (http://prevention.nih.gov/p2p/pcos/resources.aspx)
  3. Knochenhauer, 1998, Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study, J. Clin. Endocrinol. Metab., 83, 3078
  4. Michelmore, 1999, Polycystic ovaries and associated clinical and biochemical features in young women, Clin. Endocrinol. (Oxf.), 51, 779, 10.1046/j.1365-2265.1999.00886.x · DOI · Paper page
  5. Diamanti-Kandarakis, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, J. Clin. Endocrinol. Metab., 84, 4006, 10.1210/jcem.84.11.6148 · DOI · Paper page
  6. Asunción, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J. Clin. Endocrinol. Metab., 85, 2434
  7. Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J. Clin. Endocrinol. Metab., 89, 2745, 10.1210/jc.2003-032046 · DOI · Paper page
  8. Moran, 2010, Prevalence of polycystic ovary syndrome and related disorders in Mexican women, Gynecol. Obstet. Invest., 69, 274, 10.1159/000277640 · DOI · Paper page
  9. Mehrabian, 2011, The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria, Endokrynol. Pol., 62, 238
  10. Boyle, 2012, Prevalence of polycystic ovary syndrome in a sample of indigenous women in Darwin, Australia, Med. J. Aust., 196, 62, 10.5694/mja11.10553 · DOI · Paper page
  11. Gill, 2012, Prevalence of polycystic ovary syndrome in young women from North India: a community-based study, Indian J. Endocrinol. Metab., 16, S389, 10.4103/2230-8210.104104 · DOI · Paper page
  12. Li, 2013, Prevalence of polycystic ovary syndrome in women in China: a large community-based study, Hum. Reprod., 28, 2562, 10.1093/humrep/det262 · DOI · Paper page
  13. Musmar, 2013, Epidemiology of polycystic ovary syndrome a cross sectional study of university students at An-Najah national university-Palestine, Reprod. Biol. Endocrinol., 11, 47, 10.1186/1477-7827-11-47 · DOI · Paper page
  14. Rashidi, 2014, To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran, Eur. J. Obstet. Gynecol. Reprod. Biology, 174, 100, 10.1016/j.ejogrb.2013.12.018 · DOI
  15. Labrie, 2005, Is dehydroepiandrosterone a hormone?, J. Endocrinol., 187, 169, 10.1677/joe.1.06264 · DOI · Paper page
  16. Lin, 1993, Steroid 17α-hydroxylase and 17,20 lyase activities of P450c17: contributions of serine106 and P450 reductase, Endocrinology, 132, 2498, 10.1210/endo.132.6.8504753 · doi:10.1210/endo.132.6.8504753 · Paper page
  17. Longcope, 1986, Adrenal and gonadal androgen secretion in normal females, Clin. Endocrinol. Metab., 15, 213, 10.1016/S0300-595X(86)80021-4 · DOI · Paper page
  18. Rijk, 2012, Bovine liver slices: a multifunctional in vitro model to study the prohormone dehydroepiandrosterone (DHEA), Toxicol. In Vitro, 26, 1014, 10.1016/j.tiv.2012.04.012 · DOI
  19. Labrie, 2007, Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women, J. Steroid Biochem. Mol. Biol., 107, 57, 10.1016/j.jsbmb.2007.02.007 · DOI
  20. Kumar, 2005, Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS), Clin. Endocrinol. (Oxf.), 62, 644, 10.1111/j.1365-2265.2005.02256.x · DOI · Paper page
  21. Dharia, 2005, Effects of aging on cytochrome b5 expression in the human adrenal gland, J. Clin. Endocrinol. Metab., 90, 4357, 10.1210/jc.2005-0017 · DOI · Paper page
  22. Stanczyk, 2006, Diagnosis of hyperandrogenism: biochemical criteria, Best Pract. Res. Clin. Endocrinol. Metab., 20, 177, 10.1016/j.beem.2006.03.007 · DOI
  23. Carmina, 1992, The ratio of androstenedione-11β-hydroxyandrostenedione is an important marker of adrenal androgen excess in women, Fertil. Steril., 58, 1148, 10.1016/S0015-0282(16)55152-8 · DOI
  24. Hoffman, 1984, The prevalence and significance of elevated dehydroepiandrosterone sulfate levels in anovulatory women, Fertil. Steril., 42, 76, 10.1016/S0015-0282(16)47961-6 · DOI
  25. Steinberger, 1984, Testosterone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate in hyperandrogenic women, J. Clin. Endocrinol. Metab., 59, 471, 10.1210/jcem-59-3-471 · DOI
  26. Carmina, 1986, Increased DHEAS levels in PCO syndrome: evidence for the existence of two subgroups of patients, J. Endocrinol. Invest., 9, 5, 10.1007/BF03348052 · DOI
  27. Moran, 1999, Adrenal androgen excess in hyperandrogenism: relation to age and body mass, Fertil. Steril., 71, 671, 10.1016/S0015-0282(98)00536-6 · DOI
  28. Sánchez, 2002, Adrenal progestogen and androgen production in 21-hydroxylase-deficient nonclassic adrenal hyperplasia is partially independent of adrenocorticotropic hormone stimulation, Fertil. Steril., 77, 750, 10.1016/S0015-0282(01)03236-8 · DOI
  29. Miller, 1996, Follow-up study of adolescent girls with a history of premature pubarche, J. Adolesc. Health, 18, 301, 10.1016/1054-139X(95)00234-J · DOI
  30. Ibanez, 1997, Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing, Fertil. Steril., 67, 849, 10.1016/S0015-0282(97)81396-9 · DOI
  31. Meas, 2002, Endocrine consequences of premature pubarche in post-pubertal Caucasian girls, Clin. Endocrinol. (Oxf.), 57, 101, 10.1046/j.1365-2265.2002.01579.x · DOI · Paper page
  32. Ibanez, 2000, Premature adrenarche – normal variant or forerunner of adult disease?, Endocr. Rev., 21, 671
  33. Maliqueo, 2009, Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 94, 3282, 10.1210/jc.2009-0427 · DOI
  34. Lobo, 1983, Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome, Am. J. Obstet. Gynecol., 145, 496, 10.1016/0002-9378(83)90324-1 · DOI
  35. Levin, 1991, Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?, Fertil. Steril., 56, 635, 10.1016/S0015-0282(16)54592-0 · DOI
  36. Carmina, 1994, Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Fertil. Steril., 62, 738, 10.1016/S0015-0282(16)56998-2 · DOI
  37. Falhammar, 2008, A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation, J. Endocrinol. Invest., 31, 176, 10.1007/BF03345586 · DOI
  38. Hague, 1990, The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives, Clin. Endocrinol., 33, 501, 10.1111/j.1365-2265.1990.tb03887.x · DOI · Paper page
  39. Jones, 1953, The use of cortisone in follicular phase disturbances, Fertil. Steril., 4, 49, 10.1016/S0015-0282(16)31144-X · DOI
  40. Azziz, 1999, Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level, J. Clin. Endocrinol. Metab., 84, 946
  41. Chang, 1982, Circulating levels of plasma adrenocorticotropin in polycystic ovary disease, J. Clin. Endocrinol. Metab., 54, 1265, 10.1210/jcem-54-6-1265 · DOI
  42. Horrocks, 1983, ACTH function in women with the polycystic ovarian syndrome, Clin. Endocrinol., 19, 143, 10.1111/j.1365-2265.1983.tb02976.x · DOI
  43. Mongioi, 1988, Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome, J. Endocrinol. Invest., 11, 637, 10.1007/BF03350202 · doi:10.1007/bf03350202
  44. Cunningham, 1988, Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women, J. Endocrinol. Invest., 11, 247, 10.1007/BF03350147 · doi:10.1007/bf03350147
  45. Carmina, 1990, Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women, Fertil. Steril., 54, 245, 10.1016/S0015-0282(16)53697-8 · DOI
  46. Carmina, 1990, Pituitary adrenal responses to ovine corticotropin releasing hormone in polycystic ovary syndrome and other hyperandrogenic patients, Gynecol. Endocrinol., 4, 225, 10.3109/09513599009024976 · DOI
  47. Stewart, 1993, The hypothalamo–pituitary–adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome, Clin. Endocrinol. (Oxf.), 38, 387, 10.1111/j.1365-2265.1993.tb00519.x · DOI · Paper page
  48. Lanzone, 1995, Corticotropin-releasing hormone induces and exaggerated response of adrenocorticotropic hormone and cortisol in polycystic ovary syndrome, Fertil. Steril., 63, 1195, 10.1016/S0015-0282(16)57596-7 · DOI
  49. Azziz, 1998, Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic–pituitary–adrenal axis, J. Clin. Endocrinol. Metab., 83, 2317
  50. Gennarelli, 1999, Response of the pituitary–adrenal axis to hypoglycemic stress in women with the polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 84, 76, 10.1210/jcem.84.1.5403 · DOI
  51. Invitti, 1998, Altered morning and nighttime pulsatile corticotropin and cortisol release in polycystic ovary syndrome, Metabolism, 47, 143, 10.1016/S0026-0495(98)90210-4 · DOI
  52. Cinar, 2012, Adrenocortical steroid response to ACTH in different phenotypes of non obese polycystic ovary syndrome, J. Ovarian Res., 5, 42, 10.1186/1757-2215-5-42 · DOI
  53. Glintborg, 2005, Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, Caucasian, hirsute patients compared with healthy controls, J. Clin. Endocrinol. Metab., 90, 1347, 10.1210/jc.2004-1214 · DOI · Paper page
  54. Lobo, 1981, Evidence for reduced 3 beta-ol-hydroxysteroid dehydrogenase activity in some hirsute women thought to have polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 53, 394, 10.1210/jcem-53-2-394 · DOI · Paper page
  55. Siegel, 1990, ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism, N. Engl. J. Med., 323, 849, 10.1056/NEJM199009273231301 · DOI · Paper page
  56. Azziz, 1993, 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism, Am. J. Obstet. Gynecol., 168, 889, 10.1016/S0002-9378(12)90840-6 · DOI
  57. Moran, 1999, Prevalence of 3beta-hydroxysteroid dehydrogenase-deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess, Am. J. Obstet. Gynecol., 181, 596, 10.1016/S0002-9378(99)70498-9 · DOI
  58. Lutfallah, 2002, Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency, J. Clin. Endocrinol. Metab., 87, 2611
  59. Carbunaru, 2004, The hormonal phenotype of Nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency, J. Clin. Endocrinol. Metab., 89, 783, 10.1210/jc.2003-030934 · DOI · Paper page
  60. Moran, 2004, Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess, Fertil. Steril., 81, 126, 10.1016/j.fertnstert.2003.07.008 · DOI
  61. Rodin, 1994, Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase, N. Engl. J. Med., 330, 460, 10.1056/NEJM199402173300703 · DOI · Paper page
  62. Pasquali, 1998, Pulsatile secretion of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution, Clin. Endocrinol., 48, 603, 10.1046/j.1365-2265.1998.00458.x · DOI · Paper page
  63. Andrew, 1998, Obesity and gender influence cortisol secretion and metabolism in man, J. Clin. Endocrinol. Metab., 83, 1806, 10.1210/jcem.83.5.4951 · doi:10.1210/jcem.83.5.4951 · Paper page
  64. Gambineri, 2009, Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome, J. Endocrinol. Invest., 32, 210, 10.1007/BF03346454 · DOI
  65. Carmina, 2007, Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes, J. Endocrinol. Invest., 30, 111, 10.1007/BF03347408 · DOI
  66. Azziz, 1991, The effects of prolonged hypertestosteronemia on adrenocortical biosynthesis in oophorectomized women, J. Clin. Endocrinol. Metab., 72, 1025, 10.1210/jcem-72-5-1025 · DOI
  67. Hines, 2001, Influence of insulin and testosterone on adrenocortical steroidogenesis in vitro: preliminary studies, Fertil. Steril., 76, 730, 10.1016/S0015-0282(01)02014-3 · DOI
  68. Kumar, 2009, Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-H295R adrenocortical cell line, Fertil. Steril., 92, 793, 10.1016/j.fertnstert.2008.05.076 · DOI
  69. Azziz, 1998, Role of the ovary in the adrenal androgen excess of hyperandrogenic women, Fertil. Steril., 69, 851, 10.1016/S0015-0282(98)00033-8 · DOI
  70. Gonzalez, 1991, Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome, Am. J. Obstet. Gynecol., 165, 535, 10.1016/0002-9378(91)90280-5 · DOI
  71. Carmina, 1995, Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome, Obstet. Gynecol., 6, 26
  72. Cedars, 1992, Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction, Fertil. Steril., 57, 495, 10.1016/S0015-0282(16)54890-0 · DOI
  73. Azziz, 2013, Effect of bilateral oophorectomy on adrenocortical function in women with polycystic ovary syndrome, Fertil. Steril., 99, 599, 10.1016/j.fertnstert.2012.10.016 · DOI
  74. Burghen, 1980, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, J. Clin. Endocrinol. Metab., 50, 113, 10.1210/jcem-50-1-113 · DOI · Paper page
  75. Brennan, 2009, Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome, Fertil. Steril., 91, 1848, 10.1016/j.fertnstert.2008.02.101 · DOI
  76. Kauffman, 2006, Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome, Fertil. Steril., 85, 1010, 10.1016/j.fertnstert.2005.09.046 · DOI
  77. Buyalos, 1991, No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease, Fertil. Steril., 56, 1179, 10.1016/S0015-0282(16)54738-4 · DOI
  78. Buyalos, 1997, Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome, Hum. Reprod., 12, 1138, 10.1093/humrep/12.6.1138 · DOI
  79. Azziz, 1995, Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1–24) stimulation in hyperandrogenic women, Am. J. Obstet. Gynecol., 172, 1251, 10.1016/0002-9378(95)91488-9 · DOI
  80. Ludwig, 2009, Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome, Fertil. Steril., 92, 271, 10.1016/j.fertnstert.2008.05.052 · DOI
  81. Diamond, 1991, Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women, J. Clin. Endocrinol. Metab., 72, 883, 10.1210/jcem-72-4-883 · DOI · Paper page
  82. Farah-Eways, 2004, Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome, Fertil. Steril., 81, 120, 10.1016/j.fertnstert.2003.05.008 · DOI
  83. Falcone, 1990, Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women, J. Clin. Endocrinol. Metab., 71, 1653, 10.1210/jcem-71-6-1653 · DOI
  84. Azziz, 2003, Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome, Fertil. Steril., 79, 932, 10.1016/S0015-0282(02)04914-2 · DOI
  85. Rautio, 2006, Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study, Hum. Reprod., 21, 1400, 10.1093/humrep/dei505 · DOI · Paper page
  86. Sepilian, 2005, Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance, J. Clin. Endocrinol. Metab., 90, 60, 10.1210/jc.2004-1376 · DOI · Paper page
  87. Guido, 2004, Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome, Hum. Reprod., 19, 534, 10.1093/humrep/deh145 · DOI
  88. Romualdi, 2007, Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome, Fertil. Steril., 88, 131, 10.1016/j.fertnstert.2006.11.076 · DOI
  89. Aigner, 2009, Retinol-binding protein 4 in polycystic ovary syndrome – association with steroid hormones and response to pioglitazone treatment, J. Clin. Endocrinol. Metab., 94, 1229, 10.1210/jc.2008-2156 · DOI · Paper page
  90. Glintborg, 2009, A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome, Fertil. Steril., 91, 842, 10.1016/j.fertnstert.2007.12.082 · DOI
  91. Li, 2011, Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis, Clin. Endocrinol. (Oxf.), 74, 332, 10.1111/j.1365-2265.2010.03917.x · DOI · Paper page
  92. Majuri, 2007, Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study, Eur. J. Endocrinol., 156, 263, 10.1530/eje.1.02331 · DOI · Paper page
  93. Sepilian, 2006, Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens, Fertil. Steril., 85, 1441, 10.1016/j.fertnstert.2005.10.038 · DOI
  94. la Marca, 1999, Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome, Fertil. Steril., 72, 985, 10.1016/S0015-0282(99)00407-0 · DOI
  95. Forney, 1981, Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia, J. Clin. Endocrinol. Metab., 53, 192, 10.1210/jcem-53-1-192 · DOI · Paper page
  96. Ackerman, 1981, Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture, J. Clin. Endocrinol. Metab., 53, 412, 10.1210/jcem-53-2-412 · DOI · Paper page
  97. Azziz, 1991, Effect of obesity on the response to acute adrenocorticotropin stimulation in eumenorrheic women, Fertil. Steril., 56, 427, 10.1016/S0015-0282(16)54535-X · DOI
  98. Vicennati, 1998, Secretion of major adrenal androgens following ACTH administration in obese women with different body fat distribution, Hormone Metab. Res., 30, 133, 10.1055/s-2007-978851 · DOI
  99. Rittmaster, 1993, The role of adrenal hyperandrogenism, insulin resistance, and obesity in the pathogenesis of polycystic ovarian syndrome, J. Clin. Endocrinol. Metab., 76, 1295
  100. Brody, 1987, Adrenal steroids in post-menopausal women relation to obesity and to bone mineral content, Maturitas, 9, 25, 10.1016/0378-5122(87)90048-X · DOI
  101. Komindr, 1986, Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1–24) in normal and obese, nonhirsute, eumenorrheic women, J. Clin. Endocrinol. Metab., 63, 860, 10.1210/jcem-63-4-860 · DOI
  102. Vicennati, 2000, Abnormalities of the hypothalamic-pituitary-adrenal axis in nondepressed women with abdominal obesity and relations with insulin resistance: evidence for a central and a peripheral alteration, J. Clin. Endocrinol. Metab., 85, 4093, 10.1210/jcem.85.11.6946 · doi:10.1210/jcem.85.11.6946 · Paper page
  103. Rotter, 1985, A genetic component to the variation of dehydroepiandrosterone sulfate, Metabolism, 34, 731, 10.1016/0026-0495(85)90023-X · DOI
  104. Prom-Wormley, 2011, Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men, Psychoneuroendocrinology, 36, 1441, 10.1016/j.psyneuen.2011.03.018 · DOI
  105. Rice, 1993, The Cincinnati Myocardial Infarction and Hormone Family study: family resemblance for dehydroepiandrosterone sulfate in control and myocardial infarction families, Metabolism, 42, 1284, 10.1016/0026-0495(93)90126-9 · DOI
  106. An, 2001, Race differences in the pattern of familial aggregation for dehydroepiandrosterone sulfate and its responsiveness to training in the HERITAGE Family Heart Study, Metabolism, 50, 916, 10.1053/meta.2001.24926 · DOI
  107. Jaquish, 1996, Quantitative genetics of dehydroepiandrosterone sulfate and its relation to possible cardiovascular disease risk factors in Mexican Americans, Hum. Hered., 46, 301, 10.1159/000154368 · DOI
  108. Mitchell, 1996, Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study, Circulation, 94, 2159, 10.1161/01.CIR.94.9.2159 · DOI · Paper page
  109. Jaquish, 1996, Genetic correlations between lipoprotein phenotypes and indicators of sex hormone levels in Mexican Americans, Atherosclerosis, 122, 117, 10.1016/0021-9150(96)05796-6 · DOI
  110. Li, 2007, Change of dehydroepiandrosterone in serum of 6-18 year-old twin girls in Qingdao city, Wei Sheng Yan Jiu, 36, 41
  111. Meikle, 1988, Heritability of variation of plasma cortisol levels, Metabolism, 37, 514, 10.1016/0026-0495(88)90164-3 · DOI
  112. Meikle, 1997, Age genetic, and nongenetic factors influencing variation in serum sex steroids and zonal volumes of the prostate and benign prostatic hyperplasia in twins, Prostate, 33, 105, 10.1002/(SICI)1097-0045(19971001)33:2<105::AID-PROS4>3.0.CO;2-J · DOI · Paper page
  113. Nestler, 2002, Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects, J. Clin. Endocrinol. Metab., 87, 682, 10.1210/jcem.87.2.8240 · DOI
  114. Akamine, 1980, Studies on changes in the concentration of serum adrenal androgens in pubertal twins, Acta Endocrinol. (Copenh.), 93, 356
  115. Yildiz, 2006, Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters, Fertil. Steril., 86, 1688, 10.1016/j.fertnstert.2006.05.045 · DOI
  116. Franks, 2008, Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries, J. Clin. Endocrinol. Metab., 93, 3396, 10.1210/jc.2008-0369 · DOI · Paper page
  117. Goodarzi, 2007, Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters, Am. J. Obstet. Gynecol., 196, e391
  118. Legro, 2002, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 87, 2134, 10.1210/jcem.87.5.8387 · doi:10.1210/jcem.87.5.8387 · Paper page
  119. Goodarzi, 2007, Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 92, 2659, 10.1210/jc.2006-2600 · DOI · Paper page
  120. Louwers, 2013, Variants in SULT2A1 affect the DHEA sulphate to DHEA ratio in patients with polycystic ovary syndrome but not the hyperandrogenic phenotype, J. Clin. Endocrinol. Metab., 98, 3848, 10.1210/jc.2013-1976 · DOI · Paper page
  121. Komori, 1990, Fetus-specific expression of a form of cytochrome P-450 in human livers, Biochemistry, 29, 4430, 10.1021/bi00470a024 · DOI · Paper page
  122. Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat. Genet., 27, 383, 10.1038/86882 · DOI · Paper page
  123. Smit, 2005, A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels, J. Clin. Endocrinol. Metab., 90, 5313, 10.1210/jc.2005-0307 · DOI · Paper page
  124. Goodarzi, 2008, Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 93, 2909, 10.1210/jc.2008-0403 · DOI
  125. Escobar-Morreale, 1999, The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype–genotype correlations, Fertil. Steril., 72, 629, 10.1016/S0015-0282(99)00317-9 · DOI
  126. Witchel, 2005, Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess, Fertil. Steril., 83, 371, 10.1016/j.fertnstert.2004.10.027 · DOI
  127. Vandenput, 2014, Genome-wide association studies on serum sex steroid levels, Mol. Cell. Endocrinol., 382, 758, 10.1016/j.mce.2013.03.009 · DOI
  128. Zhai, 2011, Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms, PLoS Genet., 7, e1002025, 10.1371/journal.pgen.1002025 · DOI · Paper page
  129. Cui, 2013, Genotype–phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women, Hum. Reprod., 28, 538, 10.1093/humrep/des424 · DOI · Paper page
  130. Khaw, 1996, Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease, J. Endocrinol., 150, S149
  131. Ohlsson, 2010, Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men, J. Clin. Endocrinol. Metab., 95, 4406, 10.1210/jc.2010-0760 · DOI
  132. Shufelt, 2010, DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health? National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE), J. Clin. Endocrinol. Metab., 95, 4985, 10.1210/jc.2010-0143 · DOI · Paper page

Cited by

See all 188

Metadata

Authors
Goodarzi, M. O., Carmina, E., & Azziz, R.
Venue
The Journal of Steroid Biochemistry and Molecular Biology
Publisher
Elsevier BV
Published
2015-01
Volume
145
Pages
213-225
ISSN
0960-0760 (ISSN-L)
OpenAlex
W2011497283
Cited by
188
References
31
FWCI
10.95
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.